Recursion Pharmaceuticals, Inc. Stock Analysis & AI Score
Recursion Pharmaceuticals, Inc. (RXRX) has an ST Score of 47.7 (C+), driven by its Momentum (B+) and held back by its Financial Strength (D+). Analysts rate it Hold with a $5.30 price target (+36.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Recursion Pharmaceuticals, Inc. (RXRX) has an ST Score of 47.7 (C+), driven by its Momentum (B+) and held back by its Financial Strength (D+). Analysts rate it Hold with a $5.30 price target (+36.2% upside).
- Strongest
- MomentumB+
- Weakest
- Financial StrengthD+
All factor grades
- MomentumB+
- ValuationB
- ForecastB
- ProfitabilityC+
- GrowthC-
- Financial StrengthD+
- Piotroski3/9
Contact
RXRX stock: frequently asked questions
What is RXRX's ST Score?
Recursion Pharmaceuticals, Inc. (RXRX) has an ST Score of 47.7 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RXRX a buy, hold, or sell?
Analysts rate RXRX a Hold, with a price target of $5.30 (+36.2% vs the current price). Our ST Score grades it C+ (47.7/100). The ST Score is a data-driven signal, not a recommendation.
What are RXRX's factor grades?
Valuation B, Profitability C+, Financial Strength D+, Momentum B+, Growth C-, Forecast B.
What is RXRX's valuation grade?
Recursion Pharmaceuticals, Inc. (RXRX) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RXRX's growth grade?
Recursion Pharmaceuticals, Inc. (RXRX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RXRX's profitability grade?
Recursion Pharmaceuticals, Inc. (RXRX) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RXRX's financial strength grade?
Recursion Pharmaceuticals, Inc. (RXRX) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RXRX?
The average analyst price target for Recursion Pharmaceuticals, Inc. (RXRX) is $5.30 from 10 analysts, which is +36.2% versus the recent price of $3.89.
What is RXRX's Piotroski score?
Recursion Pharmaceuticals, Inc. (RXRX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.